{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:00:07Z","timestamp":1789707607258,"version":"4.0.1"},"reference-count":295,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bioorg.2024.108076","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:01:30Z","timestamp":1734634890000},"page":"108076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Current development in sulfonamide derivatives to enable CNS-drug discovery"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9243-9042","authenticated-orcid":false,"given":"Klaudia","family":"Blicharz-Futera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0252-6783","authenticated-orcid":false,"given":"Micha\u0142","family":"Kami\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-251X","authenticated-orcid":false,"given":"Katarzyna","family":"Grychowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7940-9500","authenticated-orcid":false,"given":"Vittorio","family":"Canale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-8721","authenticated-orcid":false,"given":"Pawe\u0142","family":"Zajdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.108076_b0005","article-title":"Further progress in chemotherapy of bacterial infections - N","author":"Gerhard","year":"1947","journal-title":"Nobel Lecture"},{"key":"10.1016\/j.bioorg.2024.108076_b0010","unstructured":"J.E. Lesch, The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine."},{"key":"10.1016\/j.bioorg.2024.108076_b0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejmech.2018.11.017","article-title":"Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review","volume":"162","author":"Zhao","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","article-title":"The global burden of neurological disorders: translating evidence into policy","volume":"19","author":"Feigin","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bioorg.2024.108076_b0025","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/TCRM.S323387","article-title":"Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: A comprehensive literature review","volume":"17","author":"Ruangritchankul","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.bioorg.2024.108076_b0030","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/728983","article-title":"New acetylcholinesterase inhibitors for Alzheimer\u2019s disease","author":"Mehta","year":"2012","journal-title":"Int J Alzheimers Dis"},{"key":"10.1016\/j.bioorg.2024.108076_b0035","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1021\/acs.jcim.0c00496","article-title":"Discovery of a new donepezil-like acetylcholinesterase inhibitor for targeting Alzheimer\u2019s disease: Computational studies with biological validation","volume":"60","author":"Akhoon","year":"2020","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bioorg.2024.108076_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26061658","article-title":"Novel donepezil-arylsulfonamide hybrids as multitarget-directed ligands for potential treatment of Alzheimer\u2019s disease","volume":"26","author":"Queda","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.108076_b0045","article-title":"Investigation, scaffold hopping of novel donepezil-based compounds as anti-Alzhiemer\u2019s agents: synthesis, in-silico and pharmacological evaluations","volume":"14","author":"Gupta","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.bioorg.2024.108076_b0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrn1035","article-title":"Neurobiology of butyrylcholinesterase","volume":"4","author":"Darvesh","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b0055","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.1021\/jm501195e","article-title":"Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor","volume":"57","author":"Brus","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0060","doi-asserted-by":"crossref","DOI":"10.1038\/srep39495","article-title":"Development of an in-vivo active reversible butyrylcholinesterase inhibitor","volume":"6","author":"Ko\u0161ak","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bioorg.2024.108076_b0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bioorg.2015.11.002","article-title":"Novel biphenyl bis-sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies","volume":"64","author":"Mutahir","year":"2016","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119742","article-title":"Exploring the Potential of Sulfonamide-Dihydropyridine Hybrids as Multitargeted Ligands for Alzheimer\u2019s Disease Treatment","volume":"24","author":"Dakhlaoui","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bioorg.2024.108076_b0075","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1021\/acs.biochem.9b00401","article-title":"Structure and Function of the \u03b3-Secretase Complex","volume":"58","author":"Wolfe","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2024.108076_b0080","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.4103\/1673-5374.313041","article-title":"BACE1 role in Alzheimer\u2019s disease and other dementias: From the theory to the practice","volume":"16","author":"Cervellati","year":"2021","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.bioorg.2024.108076_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2017.00097","article-title":"Physiological functions of the \u03b2-site amyloid precursor protein cleaving enzyme 1 and 2","volume":"10","author":"Yan","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b0090","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1021\/acs.jmedchem.6b00307","article-title":"Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A \u03b2-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer\u2019s Disease","volume":"59","author":"Scott","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0100","unstructured":"N., Kobayashi, K., Ueda, N., Itoh, S., Suzuki, G., Sakaguchi, A., Kato, A., Yukimasa, A., Hori, Y., Koriyama, H., Haraguchi, K., Yasui, Y. Kanda, Preparation of 2-aminodihydrothiazine derivatives as \u03b2secretase inhibitors WO 2007049532 2007 A1."},{"key":"10.1016\/j.bioorg.2024.108076_b0105","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1021\/acs.jmedchem.9b00309","article-title":"Structure-Based Design of Selective \u03b2-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2","volume":"62","author":"Fujimoto","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","article-title":"\u03b3-Secretase in Alzheimer\u2019s disease","volume":"54","author":"Hur","year":"2022","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.bioorg.2024.108076_b0115","article-title":"Notch signaling pathway: architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bioorg.2024.108076_b0120","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/jm990622z","article-title":"Fenchylamine sulfonamide inhibitors of amyloid \u03b2 peptide production by the \u03b3-secretase proteolytic pathway: Potential small-molecule therapeutic agents for the treatment of Alzheimer\u2019s disease [2]","volume":"43","author":"Rishton","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0125","doi-asserted-by":"crossref","first-page":"8717","DOI":"10.1021\/acs.jmedchem.8b00828","article-title":"Amino Acid Hot Spots of Halogen Bonding: A Combined Theoretical and Experimental Case Study of the 5-HT7 Receptor","volume":"61","author":"Kurczab","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0130","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1016\/j.bmcl.2009.07.092","article-title":"Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole\/sulfonamide based dihydroquinoline \u03b3-secretase inhibitors","volume":"19","author":"Truong","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0135","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.bmcl.2010.02.039","article-title":"Discovery of a novel sulfonamide-pyrazolopiperidine series as potent and Efficacious \u03b3-Secretase Inhibitors","volume":"20","author":"Ye","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0140","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1016\/j.bmcl.2011.08.008","article-title":"Design, synthesis and structure-activity relationship of novel [3.3.1] bicyclic sulfonamide-pyrazoles as potent \u03b3-secretase inhibitors","volume":"21","author":"Aubele","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0145","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1021\/jm301741t","volume":"56","author":"Probst","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0150","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/cn2000469","article-title":"ACS chemical neuroscience molecule spotlight on ELND006: Another \u03b3-secretase inhibitor fails in the clinic","volume":"2","author":"Hopkins","year":"2011","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b0155","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1016\/j.bmcl.2007.06.022","article-title":"N-(5-Chloro-2-(hydroxymethyl)-N-alkyl-arylsulfonamides as \u03b3-secretase inhibitors","volume":"17","author":"Parker","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0160","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.bmcl.2007.11.102","article-title":"Carbamate-appended N-alkylsulfonamides as inhibitors of \u03b3-secretase","volume":"18","author":"Bergstrom","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0165","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bmcl.2007.10.105","article-title":"Nitrogen-appended N-alkylsulfonamides as inhibitors of \u03b3-secretase","volume":"18","author":"Bergstrom","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0170","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/ml1000239","article-title":"Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable \u03b3-secretase inhibitor","volume":"1","author":"Gillman","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0175","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal Alzheimer disease with avagacestat: A randomized clinical trial","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.bioorg.2024.108076_b0180","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1021\/jm801252w","article-title":"Discovery of begacestat, a Notch-1-sparing \u03b3-secretase inhibitor for the treatment of Alzheimer\u2019s disease","volume":"51","author":"Mayer","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0185","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/jpet.109.152975","article-title":"Begacestat (GSI-953): A novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein \u03b3-secretase for the treatment of Alzheimer\u2019s disease","volume":"331","author":"Martone","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2024.108076_b0190","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/pr.118.015552","article-title":"International union of basic and clinical pharmacology. Cx. Classification of receptors for 5-hydroxytryptamine; pharmacology and function","volume":"73","author":"Barnes","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bioorg.2024.108076_b0195","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/sj.bjp.0703458","article-title":"Characterization of [125I]-SB-258585 binding to human recombinant and native 5-HT6 receptors in rat, pig and human brain tissue","volume":"130","author":"Hirst","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bioorg.2024.108076_b0200","unstructured":"Y. Tsai, M. Dukat, A. Slassi, N. Maclean, L. Demchyshyn, J.E. Savage, B.L. Roth, S. Hufesein, M. Lee, R.A. Glennon, N 1-(Benzenesulfonyl)tryptamines as Novel 5-HT 6 Antagonists, n.d."},{"key":"10.1016\/j.bioorg.2024.108076_b0205","doi-asserted-by":"crossref","unstructured":"N. Upton, T. Chuang, A.J. Hunter, D.J. Virley, 5-HT 6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer\u2019s Disease, n.d. http:\/\/www.gsk.com\/investors\/presentations\/.","DOI":"10.1016\/j.nurt.2008.05.008"},{"key":"10.1016\/j.bioorg.2024.108076_b0210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13195-018-0368-9","article-title":"A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer\u2019s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil","volume":"10","author":"Fullerton","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.bioorg.2024.108076_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020309","article-title":"Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders","volume":"13","author":"Nirogi","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2024.108076_b0220","doi-asserted-by":"crossref","unstructured":"R. Nirogi A. Shinde R.S. Kambhampati A.R. Mohammed S.K. Saraf R. kumar Badange, T.R. Bandyala, V. Bhatta, K. Bojja, V. Reballi, R. Subramanian, V. Benade, R.C. Palacharla, G. Bhyrapuneni, P. Jayarajan, V. Goyal, V. Jasti, Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer\u2019s Disease J Med Chem 60 2017 1843 1859 10.1021\/acs.jmedchem.6b01662.","DOI":"10.1021\/acs.jmedchem.6b01662"},{"key":"10.1016\/j.bioorg.2024.108076_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/gps.5813","article-title":"Potential beneficial effects of masupirdine (SUVN-502) on agitation\/aggression and psychosis in patients with moderate Alzheimer\u2019s disease: Exploratory post hoc analyses","volume":"37","author":"Nirogi","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.bioorg.2024.108076_b0230","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease three randomized clinical trials, in","author":"Atri","year":"2018","journal-title":"JAMA - Journal of the American Medical Association, American Medical Association"},{"key":"10.1016\/j.bioorg.2024.108076_b0235","article-title":"The 5-HT6 receptor interactome: New insight in receptor signaling and its impact on brain physiology and pathologies","author":"Chaumont-Dubel","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2024.108076_b0240","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/emmm.201201410","article-title":"5-HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia","volume":"4","author":"Meffre","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.bioorg.2024.108076_b0245","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nchembio.1547","article-title":"Cdk5 induces constitutive activation of 5-HT 6 receptors to promote neurite growth","volume":"10","author":"Duhr","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bioorg.2024.108076_b0250","doi-asserted-by":"crossref","first-page":"12310","DOI":"10.1073\/pnas.1600914113","article-title":"Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity","volume":"113","author":"Nadim","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bioorg.2024.108076_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2020.101846","article-title":"mTOR activation by constitutively active serotonin6 receptors as new paradigm in neuropathic pain and its treatment","volume":"193","author":"Martin","year":"2020","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bioorg.2024.108076_b0260","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1021\/acschemneuro.6b00090","article-title":"Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer\u2019s Disease","volume":"7","author":"Grychowska","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b0270","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ejmech.2017.12.053","article-title":"Novel non-sulfonamide 5-HT6 receptor partial inverse agonist in a group of imidazo[4,5-b]pyridines with cognition enhancing properties","volume":"144","author":"Vanda","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0275","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c02009","article-title":"Imidazopyridine-Based 5-HT6 Receptor Neutral Antagonists: Impact of N1-Benzyl and N1-Phenylsulfonyl Fragments on Different Receptor Conformational States","author":"Vanda","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116615","article-title":"5-HT6 receptor neutral antagonists protect astrocytes: A lesson from 2-phenylpyrrole derivatives","volume":"275","author":"Drop","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0290","first-page":"63","article-title":"Novel multi-target-directed ligands for Alzheimer\u2019s disease: Combining cholinesterase inhibitors and 5-HT6 receptor antagonists","volume":"124","author":"Wi\u0119ckowska","year":"2016","journal-title":"Design, Synthesis and Biological Evaluation, Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113783","article-title":"Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT6 receptor with anti-aggregation properties against amyloid-beta and tau","volume":"225","author":"Wichur","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112765","article-title":"A dual-acting 5-HT6 receptor inverse agonist\/MAO-B inhibitor displays glioprotective and pro-cognitive properties","volume":"208","author":"Canale","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115071","article-title":"Hybrid molecules combining GABA-A and serotonin 5-HT6 receptors activity designed to tackle neuroinflammation associated with depression","volume":"247","author":"Marcinkowska","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0310","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2014.12.045","article-title":"Novel 5-HT6 receptor antagonists\/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia","volume":"92","author":"Ko\u0142aczkowski","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108099","article-title":"Dual-acting agents for improving cognition and real-world function in Alzheimer\u2019s disease: Focus on 5-HT6 and D3 receptors as hubs","volume":"177","author":"Millan","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2024.108076_b0320","doi-asserted-by":"crossref","unstructured":"K. Oscar M. Saavedra Dominique Brossard Anne Rojas Delphine Dupuis, C.M. la C. Arnaud Gohier Mark J. Millan Jean-Claude Ortuno, S. Hanessian, Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT6receptor ligands with significant selectivity for D3over D2receptors, Bioorg Med Chem 25 (2017) 38\u201352. https:\/\/doi.org\/10.1016\/j.bmc.2016.10.010.","DOI":"10.1016\/j.bmc.2016.10.010"},{"key":"10.1016\/j.bioorg.2024.108076_b0325","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/acschemneuro.8b00618","article-title":"Dual 5-HT6 and D3 Receptor Antagonists in a Group of 1 H-Pyrrolo[3,2- c]quinolines with Neuroprotective and Procognitive Activity","volume":"10","author":"Grychowska","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b0330","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/cn300095t","article-title":"5-HT4 Receptors Constitutively Promote the Non-Amyloidogenic Pathway of APP Cleavage and Interact with ADAM10","volume":"4","author":"Cochet","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b0335","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acschemneuro.5b00135","article-title":"Serotonin: A New Hope in Alzheimer\u2019s Disease?","volume":"6","author":"Claeysen","year":"2015","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b0340","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF00168686","article-title":"Effects of 5-HT4 receptor stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus","volume":"345","author":"Kilbinger","year":"1992","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bioorg.2024.108076_b0345","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/jm801327q","article-title":"Design, Synthesis, and Biological Evaluation of New 5-HT4 Receptor Agonists: Application as Amyloid Cascade Modulators and Potential Therapeutic Utility in Alzheimer\u2019s Disease","volume":"52","author":"Russo","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0350","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0028-3908(01)00123-X","article-title":"Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors","volume":"41","author":"Lamirault","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2024.108076_b0355","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejmech.2016.05.048","article-title":"Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer\u2019s disease","author":"Yahiaoui","year":"2016","journal-title":"Eur J Med Chem 121"},{"key":"10.1016\/j.bioorg.2024.108076_b0360","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1021\/acs.jmedchem.5b00115","article-title":"Novel Multitarget-Directed Ligands (MTDLs) with Acetylcholinesterase (AChE) Inhibitory and Serotonergic Subtype 4 Receptor (5-HT4R) Agonist Activities As Potential Agents against Alzheimer\u2019s Disease: The Design of Donecopride","volume":"58","author":"Rochais","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0365","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/bph.14964","article-title":"Donecopride, a Swiss army knife with potential against Alzheimer\u2019s disease","volume":"177","author":"Rochais","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bioorg.2024.108076_b0370","doi-asserted-by":"crossref","unstructured":"A.P. Davenport, T.I. Bonner, S.M. Foord, A.J. Harmar, R.R. Neubig, J.-P. Pin, M. Spedding, M. Kojima, K. Kangawa, International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function, Pharmacol Rev 57 (2005) 541. https:\/\/doi.org\/10.1124\/pr.57.4.1.","DOI":"10.1124\/pr.57.4.1"},{"key":"10.1016\/j.bioorg.2024.108076_b0375","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.neuroscience.2008.03.015","article-title":"Decreased memory for novel object recognition in chronically food-restricted mice is reversed by acute ghrelin administration","volume":"153","author":"Carlini","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.bioorg.2024.108076_b0380","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1016\/j.bmcl.2007.09.067","article-title":"Potent achiral agonists of the ghrelin (growth hormone secretagogue) receptor. Part I: Lead identification","volume":"17","author":"Heightman","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0385","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.bmcl.2007.12.021","article-title":"Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: Lead optimisation","volume":"18","author":"Witherington","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0390","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-009-1620-6","article-title":"Cognitive enhancing effects of ghrelin receptor agonists","volume":"206","author":"Atcha","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bioorg.2024.108076_b0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02538","article-title":"Pharmacological inhibitors of the nlrp3 inflammasome","volume":"10","author":"Zahid","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.bioorg.2024.108076_b0400","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2024.108076_b0405","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.12458","article-title":"Mechanism of NLRP3 inflammasome activation","volume":"1319","author":"Sutterwala","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bioorg.2024.108076_b0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.796867","article-title":"The Impact of Systemic Inflammation on Alzheimer\u2019s Disease Pathology","volume":"12","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bioorg.2024.108076_b0415","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents -synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bioorg.2024.108076_b0420","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1021\/acsmedchemlett.9b00433","article-title":"Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors","volume":"11","author":"Agarwal","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0450","first-page":"1078","article-title":"Is Alzheimer\u2019s disease a Type 3 Diabetes?","volume":"2017","author":"Kandimalla","year":"1863","journal-title":"A Critical Appraisal, Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.bioorg.2024.108076_b0425","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","article-title":"A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse","volume":"63","author":"Marchetti","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.bioorg.2024.108076_b0430","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.200903124","article-title":"Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome","volume":"187","author":"Lamkanfi","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bioorg.2024.108076_b0435","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/acschemneuro.7b00124","article-title":"Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis","volume":"8","author":"Guo","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b0440","doi-asserted-by":"crossref","unstructured":"Y. Xu, Y. Xu, H. Blevins, C. Guo, S. Biby, X.-Y. Wang, C. Wang, S. Zhang, Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies, 2022. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114468.","DOI":"10.1016\/j.ejmech.2022.114468"},{"key":"10.1016\/j.bioorg.2024.108076_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115750","article-title":"Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023","volume":"260","author":"Duan","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0455","unstructured":"G.V. Born, L.D. Ganten, B.H. Herken, B.K. Starke, F.P. Br Taylor, L. Jolla, Handbook of Experimental Pharmacology Volume 144 Editorial Board, n.d."},{"key":"10.1016\/j.bioorg.2024.108076_b0460","doi-asserted-by":"crossref","unstructured":"H. Rollema, D. Bertrand, R.S. Hurst, Nicotinic Agonists and Antagonists, in: Encyclopedia of Psychopharmacology, Springer Berlin Heidelberg, 2014: pp. 1\u201321. https:\/\/doi.org\/10.1007\/978-3-642-27772-6_304-2.","DOI":"10.1007\/978-3-642-27772-6_304-2"},{"key":"10.1016\/j.bioorg.2024.108076_b0465","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/bph.13745","article-title":"Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors Correspondence Jon Lindstrom, Department of Neuroscience, 130 A LINKED ARTICLES","volume":"175","author":"Morgan","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bioorg.2024.108076_b0470","series-title":"Cyclopropyl Aryl Amide Derivatives and Uses Thereof WO2009043784A1","year":"2009"},{"key":"10.1016\/j.bioorg.2024.108076_b0475","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1124\/jpet.113.210963","article-title":"Characterization of RO5126946, a novel \u03b17 nicotinic acetylcholine receptor-positive allosteric modulator","volume":"350","author":"Sahdeo","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2024.108076_b0480","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1021\/acsmedchemlett.9b00001","article-title":"Discovery of BNC375, a Potent, Selective, and Orally Available Type i Positive Allosteric Modulator of \u03b17 nAChRs","volume":"10","author":"Harvey","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0485","unstructured":"Brendan M. Crowley, Brian T. Campbell, Joseph L. Duffy, Thomas J. Greshock, Deodial G. Guiadeen, Andrew John Harvey, Belinda C. Huff, Kenneth J. Leavitt, Vanessa L. Rada, John M. Sanders, William D. Shipe, Linda M. Suen, Ian M. Bell, ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS US 9840481B2, 2017."},{"key":"10.1016\/j.bioorg.2024.108076_b0490","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1021\/acs.jmedchem.9b01569","volume":"63","author":"Sinha","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113189","article-title":"Discovery of novel positive allosteric modulators of the \u03b17 nicotinic acetylcholine receptor: Scaffold hopping approach","volume":"214","author":"Ledneczki","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0500","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/jnc.12509","article-title":"The GLT-1 (EAAT2; slc1a2) glutamate transporter is essential for glutamate homeostasis in the neocortex of the mouse","volume":"128","author":"Bj\u00f8rnsen","year":"2014","journal-title":"J Neurochem"},{"key":"10.1016\/j.bioorg.2024.108076_b0505","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1021\/acs.jmedchem.2c01572","article-title":"A Medicinal Chemistry Perspective on Excitatory Amino Acid Transporter 2 Dysfunction in Neurodegenerative Diseases","volume":"66","author":"Fontana","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0510","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.neuint.2005.12.001","article-title":"Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury","volume":"48","author":"Yi","year":"2006","journal-title":"Neurochem Int"},{"key":"10.1016\/j.bioorg.2024.108076_b0515","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/jcp.22609","article-title":"Role of Excitatory Amino Acid Transporter-2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics","volume":"226","author":"Kim","year":"2011","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.bioorg.2024.108076_b0520","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1021\/acs.jmedchem.6b01066","article-title":"\u03b2-Sulfonamido Functionalized Aspartate Analogues as Excitatory Amino Acid Transporter Inhibitors: Distinct Subtype Selectivity Profiles Arising from Subtle Structural Differences","volume":"59","author":"Hansen","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0525","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1021\/acsmedchemlett.0c00342","article-title":"\u03b2-Indolyloxy Functionalized Aspartate Analogs as Inhibitors of the Excitatory Amino Acid Transporters (EAATs)","volume":"11","author":"Liu","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0530","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1021\/acs.jmedchem.5b00683","article-title":"Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential","volume":"59","author":"Feng","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0535","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-5793(96)00811-3","article-title":"ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine\/threonine kinase in mice","volume":"392","author":"Nakagawa","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0540","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41398-020-00917-z","article-title":"ARHGAP10, which encodes Rho GTPase-activating protein 10, is a novel gene for schizophrenia risk","volume":"10","author":"Sekiguchi","year":"2020","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.bioorg.2024.108076_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104743","article-title":"Dysregulation of Rac or Rho elicits death of motor neurons and activation of these GTPases is altered in the G93A mutant hSOD1 mouse model of amyotrophic lateral sclerosis","volume":"136","author":"Stankiewicz","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bioorg.2024.108076_b0550","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0163-7258(98)00070-9","article-title":"H-Series Protein Kinase Inhibitors and Potential Clinical Applications","volume":"82","author":"Ono-Saito","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bioorg.2024.108076_b0555","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1167\/iovs.13-13842","article-title":"The Novel Rho Kinase (ROCK) Inhibitor K-115: A New Candidate Drug for Neuroprotective Treatment in Glaucoma","volume":"55","author":"Yamamoto","year":"2014","journal-title":"Invest Ophthalmol vis Sci"},{"key":"10.1016\/j.bioorg.2024.108076_b0560","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00018-009-0189-x","article-title":"Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity","volume":"67","author":"Hahmann","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2024.108076_b0565","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1741-7015-10-24","article-title":"Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy","volume":"10","author":"Bowerman","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.bioorg.2024.108076_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175207","article-title":"Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia","volume":"931","author":"Takase","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bioorg.2024.108076_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106589","article-title":"Inhibition of Rho-kinase ameliorates decreased spine density in the medial prefrontal cortex and methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated mutations of the Arhgap10 gene","volume":"187","author":"Tanaka","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bioorg.2024.108076_b0580","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1021\/acs.jmedchem.1c01255","article-title":"Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis","volume":"65","author":"Mart\u00edn-C\u00e1mara","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0585","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bioorg.2024.108076_b0590","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pharmthera.2018.08.010","article-title":"Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders","volume":"193","author":"Wiero\u0144ska","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bioorg.2024.108076_b0595","first-page":"306","article-title":"Cellular mechanisms of the 5-HT7 receptor-mediated signaling","author":"Guseva","year":"2014","journal-title":"Front Behav Neurosci 8"},{"key":"10.1016\/j.bioorg.2024.108076_b0600","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1523\/JNEUROSCI.1790-05.2005","article-title":"5-HT7 Receptor Is Coupled to G\u03b1 Subunits of Heterotrimeric G12-Protein to Regulate Gene Transcription and Neuronal Morphology","volume":"25","author":"Kvachnina","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bioorg.2024.108076_b0605","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nchembio.2527","article-title":"Structure-inspired design of \u03b2-arrestin-biased ligands for aminergic GPCRs","volume":"14","author":"McCorvy","year":"2018","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bioorg.2024.108076_b0610","series-title":"Proceedings of the National Academy of Sciences 119","article-title":"Serodolin, a β-arrestin–biased ligand of 5-HT7 receptor, attenuates pain-related behaviors","author":"El Khamlichi","year":"2022"},{"key":"10.1016\/j.bioorg.2024.108076_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107967","article-title":"Constitutive activity of 5-HT receptors: Factual analysis","volume":"168","author":"De Deurwaerd\u00e8re","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2024.108076_b0620","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-015-0236-0","article-title":"Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date","volume":"29","author":"Nikiforuk","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bioorg.2024.108076_b0625","doi-asserted-by":"crossref","first-page":"8475","DOI":"10.1021\/acs.jmedchem.7b01898","article-title":"Structure\u2013Activity Relationships and Therapeutic Potentials of 5-HT7 Receptor Ligands: An Update","volume":"61","author":"Modica","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0630","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuropharm.2004.11.015","article-title":"Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression","volume":"48","author":"Guscott","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2024.108076_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110532","article-title":"Activation of the 5-HT7 receptor and MMP-9 signaling module in the hippocampal CA1 region is necessary for the development of depressive-like behavior","volume":"38","author":"Bijata","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.bioorg.2024.108076_b0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156986","article-title":"An algorithm to identify target-selective ligands - A case study of 5-HT7\/5-HT1A receptor selectivity","volume":"11","author":"Kurczab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2024.108076_b0645","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/cns.12247","article-title":"Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders","volume":"20","author":"Naumenko","year":"2014","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.bioorg.2024.108076_b0650","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/jm991151j","article-title":"A novel, potent, and selective 5-HT7 antagonist: (R)-3-(2-(2-(4- methylpiperidin-1-yl)- ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970) [1]","volume":"43","author":"Lovell","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0655","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bjp.0703357","article-title":"Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist","volume":"130","author":"Hagan","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bioorg.2024.108076_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2020.101900","article-title":"Amelioration of Tau pathology and memory deficits by targeting 5-HT7 receptor","volume":"197","author":"Labus","year":"2021","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bioorg.2024.108076_b0665","unstructured":"M.W. Cohen M.P.; Filla, S.A.; Hellman, S.L.; Hollinshead, S.P.; Tidwell, Substituted piperazinyl pyrazines and pyridines as 5-ht7 receptor antagonists, WO2009029439A1, n.d."},{"key":"10.1016\/j.bioorg.2024.108076_b0670","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejmech.2012.07.043","article-title":"The multiobjective based design, synthesis and evaluation of the arylsulfonamide\/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT7 receptor antagonists","volume":"56","author":"Zajdel","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0675","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1039\/C5MD00166H","article-title":"Arylsulfonamide derivatives of (aryloxy)ethylpiperidines as selective 5-HT7 receptor antagonists and their psychotropic properties","volume":"6","author":"Zajdel","year":"2015","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.bioorg.2024.108076_b0680","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2015.11.040","article-title":"Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties","volume":"108","author":"Canale","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0685","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.bmc.2017.03.057","article-title":"Novel 5-HT(7)R antagonists, arylsulfonamide derivatives of (aryloxy)propyl piperidines: Add-on effect to the antidepressant activity of SSRI and DRI, and pro-cognitive profile","volume":"25","author":"Canale","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0690","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-019-1049-5","article-title":"Management of Behavioral and Psychological Symptoms of Dementia","volume":"21","author":"Bessey","year":"2019","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.bioorg.2024.108076_b0695","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.2174\/138920112800784880","article-title":"Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in Schizophrenia","volume":"13","author":"Meltzer","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.bioorg.2024.108076_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112149","article-title":"Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD)","volume":"191","author":"Bucki","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0705","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.bmc.2011.12.039","article-title":"Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor\u20145-HT1A\/5-HT2A\/5-HT7 and D2\/D3\/D4\u2014agents: The synthesis and pharmacological evaluation","volume":"20","author":"Zajdel","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0710","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2012.11.042","article-title":"Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A\/5-HT2A\/5-HT7 and dopamine D2\/D3 receptors","volume":"60","author":"Zajdel","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0715","first-page":"57","article-title":"Quinoline-and isoquinoline-sulfonamide analogs of aripiprazole: Novel antipsychotic agents?, Future","volume":"6","author":"Zajdel","year":"2014","journal-title":"Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0720","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ejmech.2018.01.002","article-title":"Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects","volume":"145","author":"Zajdel","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0725","unstructured":"Pawe\u0142 ZAJDEL, Krzysztof MARCINIEC, Krzysztof KAMI\u0143SKI, Vittorio CANALE, Andrzej J. BOJARSKI, Tomasz KOS, Piotr POPIK, (quinoline or isoquinoline)sulfonamides of cyclic amines as antipsychotic drugs WO2016003296A1, (2016)."},{"key":"10.1016\/j.bioorg.2024.108076_b0730","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/bph.12509","article-title":"ADN-1184 a monoaminergic ligand with 5-HT6\/7 receptor antagonist activity: Pharmacological profile and potential therapeutic utility","volume":"171","author":"Ko\u0142aczkowski","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bioorg.2024.108076_b0735","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrd.2016.28","article-title":"Altering the course of schizophrenia: Progress and perspectives","volume":"15","author":"Millan","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bioorg.2024.108076_b0740","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bioorg.2024.108076_b0745","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1016\/j.bmcl.2007.08.015","article-title":"Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile","volume":"17","author":"\u00c1gai-Csongor","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0750","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/01926230490431754","article-title":"Epididymal and Systemic Phospholipidosis in Rats and Dogs Treated with the Dopamine D3 Selective Antagonist PNU-177864","volume":"32","author":"Rudmann","year":"2004","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.bioorg.2024.108076_b0755","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/019262339702500111","article-title":"Cationic Amphiphilic Drug-Induced Phospholipidosis","author":"Halliwell","year":"1997","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.bioorg.2024.108076_b0760","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/acschemneuro.6b00297","article-title":"Dopamine D3\/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects","volume":"8","author":"Wager","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b0765","first-page":"23","article-title":"The role of 5-HT3-like receptors in the action of clozapine","volume":"55","author":"Wang","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.bioorg.2024.108076_b0770","article-title":"Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence","author":"Arnt","year":"1998","journal-title":"Ashby and Wang"},{"key":"10.1016\/j.bioorg.2024.108076_b0775","doi-asserted-by":"crossref","first-page":"13279","DOI":"10.1021\/acs.jmedchem.1c00224","article-title":"Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3and 5-HT6Receptor Antagonist with Antipsychotic and Procognitive Properties","volume":"64","author":"Zajdel","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0780","doi-asserted-by":"crossref","unstructured":"G. Campiani, A. Cappelli, V. Nacci, M. Anzini, S. Vomero, M. Hamon, A. Cagnotto, C. Fracasso, C. Uboldi, S. Caccia, S. Consolo, T. Mennini, Novel and Highly Potent 5-HT 3 Receptor Agonists Based on a Pyrroloquinoxaline Structure, 1997. https:\/\/doi.org\/10.1021\/jm970376w.","DOI":"10.1021\/jm970376w"},{"key":"10.1016\/j.bioorg.2024.108076_b0785","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0014-5793(94)01209-1","article-title":"Cloning and characterisation of the human 5-HT5A serotonin receptor","volume":"355","author":"Rees","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(98)00003-5","article-title":"Distribution of the 5-HT5A serotonin receptor mRNA in the human brain","volume":"56","author":"Pasqualetti","year":"1998","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.bioorg.2024.108076_b0795","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0006-8993(00)02273-3","article-title":"Localization of 5-ht5A receptor-like immunoreactivity in the rat brain","volume":"867","author":"Oliver","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.bioorg.2024.108076_b0800","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.mp.4000829","article-title":"Association of a 5-HT5A receptor polymorphism, Pro15Ser, to schizophrenia","volume":"6","author":"Iwata","year":"2001","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bioorg.2024.108076_b0805","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0896-6273(00)80712-6","article-title":"Increased Exploratory Activity and Altered Response to LSD in Mice Lacking the 5-HT5A Receptor","volume":"22","author":"Grailhe","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.bioorg.2024.108076_b0810","doi-asserted-by":"crossref","unstructured":"V. Balazs N.B. J., V. Szilvia, K. Diana, S. Gyula, B. Gyorgy, Medicinal Chemistry of 5-HT5A Receptor Ligands: A Receptor Subtype with Unique Therapeutical Potential Curr Top Med Chem 10 2010 554 578 https:\/\/doi.org\/http:\/\/dx.doi.org\/10.2174\/156802610791111588.","DOI":"10.2174\/156802610791111588"},{"key":"10.1016\/j.bioorg.2024.108076_b0815","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.euroneuro.2014.07.009","article-title":"ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia","volume":"24","author":"Yamazaki","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bioorg.2024.108076_b0820","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.neuropharm.2016.01.035","article-title":"The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia","volume":"105","author":"Nikiforuk","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2024.108076_b0825","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.brainres.2015.06.043","article-title":"Role of spinal 5-HT5A, and 5-HT1A\/1B\/1D, receptors in neuropathic pain induced by spinal nerve ligation in rats","volume":"1622","author":"Avila-Rojas","year":"2015","journal-title":"Brain Res"},{"key":"10.1016\/j.bioorg.2024.108076_b0830","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/S0960-894X(02)00690-X","article-title":"SB-656104-A: A novel 5-HT7 receptor antagonist with improved In vivo properties","volume":"12","author":"Forbes","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0835","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1021\/acs.jmedchem.1c02031","article-title":"Structure-Based Design of a Chemical Probe Set for the 5-HT5A Serotonin Receptor","volume":"65","author":"Levit Kaplan","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0840","doi-asserted-by":"crossref","unstructured":"T. Sakurai A. Amemiya M.I. Ishii M, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M., Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior Cell 1998 573 585 10.1016\/s0092-8674(00)80949-6.","DOI":"10.1016\/S0092-8674(00)80949-6"},{"key":"10.1016\/j.bioorg.2024.108076_b0845","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7 R)-4-(5-chloro-1,3- benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2 H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia","volume":"53","author":"Cox","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0850","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005213","article-title":"Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition","author":"Uslaner","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bioorg.2024.108076_b0855","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1172\/JCI71017","article-title":"Orexin neurons suppress narcolepsy via 2 distinct efferent pathways","volume":"124","author":"Hasegawa","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bioorg.2024.108076_b0860","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","article-title":"Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists","volume":"58","author":"Nagahara","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0865","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.1700499114","article-title":"Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models","volume":"114","author":"Irukayama-Tomobe","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bioorg.2024.108076_b0870","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsmedchemlett.1c00626","article-title":"Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist","volume":"13","author":"Fujimoto","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0875","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13878","article-title":"Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals","volume":"32","author":"Evans","year":"2023","journal-title":"J Sleep Res"},{"key":"10.1016\/j.bioorg.2024.108076_b0880","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsad049","article-title":"Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia","volume":"46","author":"Mignot","year":"2023","journal-title":"Sleep"},{"key":"10.1016\/j.bioorg.2024.108076_b0885","unstructured":"Yuichi Kajita, Satoshi Mikami, Yuhei Miyanohana, Tatsuki Koike, Masaki DAINI, Norio Oyabu, Masaki Ogino, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura, Heterocyclic compound and use thereof WO2019027058A1, 2019."},{"key":"10.1016\/j.bioorg.2024.108076_b0890","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/jpet.122.001449","article-title":"TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy","volume":"385","author":"Ishikawa","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2024.108076_b0895","doi-asserted-by":"crossref","unstructured":"R. Evans, H. Kimura, R. Alexander, C.H. Davies, H. El Ene Faessel, D.S. Hartman, T. Ishikawa, E. Ratti, K. Shimizu, M. Suzuki, S. Tanaka, H. Yukitake, Y. Dauvilliers, E. Mignot, Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients, Proc Natl Acad Sci U S A (2022). https:\/\/doi.org\/10.1073\/pnas.","DOI":"10.1073\/pnas.2207531119"},{"key":"10.1016\/j.bioorg.2024.108076_b0900","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/acs.jmedchem.6b01418","article-title":"Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies","volume":"60","author":"Nagase","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0905","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.109.152009","article-title":"Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat","volume":"330","author":"Dugovic","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2024.108076_b0910","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1016\/j.bmcl.2011.08.094","article-title":"Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists","volume":"21","author":"Fujimoto","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b0915","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bioorg.2024.108076_b0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2024.102634","article-title":"TRPV1 channel in the pathophysiology of epilepsy and its potential as a molecular target for the development of new antiseizure drug candidates","volume":"240","author":"Soca\u0142a","year":"2024","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bioorg.2024.108076_b0925","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/13543776.2019.1629419","article-title":"Carbonic anhydrases as disease markers","volume":"29","author":"Zamanova","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bioorg.2024.108076_b0930","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.772278","article-title":"Carbonic Anhydrases as Potential Targets Against Neurovascular Unit Dysfunction in Alzheimer\u2019s Disease and Stroke","volume":"13","author":"Lemon","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b0935","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26216380","article-title":"Carbonic anhydrase inhibitors and epilepsy: State of the art and future perspectives","volume":"26","author":"Ciccone","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.108076_b0940","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuint.2005.08.007","article-title":"Expression of carbonic anhydrases II, IV, VII, VIII and XII in rat brain after kainic acid induced status epilepticus","volume":"48","author":"Halmi","year":"2006","journal-title":"Neurochem Int"},{"key":"10.1016\/j.bioorg.2024.108076_b0945","unstructured":"Kadian R, Kumar A. Zonisamide. [Updated 2023 May 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507903\/, in: n.d."},{"key":"10.1016\/j.bioorg.2024.108076_b0950","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14756366.2018.1428572","article-title":"Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors?","volume":"33","author":"Supuran","year":"2018","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0955","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1021\/acs.jmedchem.6b01804","article-title":"Discovery of Benzenesulfonamides with Potent Human Carbonic Anhydrase Inhibitory and Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Assessment","volume":"60","author":"Mishra","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0960","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/cmdc.201000044","article-title":"Identification of potent and selective human carbonic anhydrase VII (hCA VII) inhibitors","volume":"5","author":"Gitto","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2024.108076_b0965","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/jm300112w","article-title":"Synthesis, structure-activity relationship studies, and X-ray crystallographic analysis of arylsulfonamides as potent carbonic anhydrase inhibitors","volume":"55","author":"Gitto","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0970","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.pain.2009.11.015","article-title":"Acetazolamide and midazolam act synergistically to inhibit neuropathic pain","volume":"148","author":"Asiedu","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.bioorg.2024.108076_b0975","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jpain.2014.01.001","article-title":"Inhibition of carbonic anhydrase augments GABAA receptor-mediated analgesia via a spinal mechanism of action","volume":"15","author":"Asiedu","year":"2014","journal-title":"J. Pain"},{"key":"10.1016\/j.bioorg.2024.108076_b0980","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bmc.2015.02.027","article-title":"A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects","volume":"23","author":"Carta","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0985","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1021\/acs.jmedchem.9b02135","article-title":"Phenyl(thio)phosphon(amid)ate Benzenesulfonamides as Potent and Selective Inhibitors of Human Carbonic Anhydrases II and VII Counteract Allodynia in a Mouse Model of Oxaliplatin-Induced Neuropathy","volume":"63","author":"Nocentini","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b0990","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a003947","article-title":"Voltage-Gated Calcium Channels","volume":"3","author":"Catterall","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bioorg.2024.108076_b0995","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/brain\/aws225","article-title":"Neurological perspectives on voltage-gated sodium channels","volume":"135","author":"Eijkelkamp","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.bioorg.2024.108076_b1000","doi-asserted-by":"crossref","unstructured":"J. Oyrer, S. Maljevic, I.E. Scheffer, S.F. Berkovic, S. Petrou, C.A. Reid, Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies, Pharmacol Rev 70 (2018) 142 LP \u2013 173. https:\/\/doi.org\/10.1124\/pr.117.014456.","DOI":"10.1124\/pr.117.014456"},{"key":"10.1016\/j.bioorg.2024.108076_b1005","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12612","article-title":"Mutations in the Scn8a DIIS4 voltage sensor reveal new distinctions among hypomorphic and null Nav1.6 sodium channels","volume":"19","author":"Inglis","year":"2020","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.bioorg.2024.108076_b1010","unstructured":"M.J. Beaudoin S., Johnson, M.S., Marron, B.E., Suto, Sodium Channel Inhibitors 2008."},{"key":"10.1016\/j.bioorg.2024.108076_b1015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1039\/C7MD00131B","article-title":"The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics","author":"Pryde","year":"2017","journal-title":"Medchemcomm 8"},{"key":"10.1016\/j.bioorg.2024.108076_b1020","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1021\/acs.jmedchem.9b01032","article-title":"Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective NaV1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy","volume":"62","author":"Focken","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1025","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/epi.13422","article-title":"SCN8A encephalopathy: Research progress and prospects","volume":"57","author":"Meisler","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.bioorg.2024.108076_b1030","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1016\/j.pain.2011.07.025","article-title":"Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice","volume":"152","author":"Obara","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.bioorg.2024.108076_b1035","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1523\/JNEUROSCI.3451-09.2009","article-title":"A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states","volume":"29","author":"G\u00e9ranton","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bioorg.2024.108076_b1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105218","article-title":"Neuropathic pain-alleviating activity of novel 5-HT6 receptor inverse agonists derived from 2-aryl-1H-pyrrole-3-carboxamide","volume":"115","author":"Drop","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1045","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020364","article-title":"The Constitutive Activity of Spinal 5-HT6 Receptors Contributes to Diabetic Neuropathic Pain in Rats","volume":"13","author":"Mokhtar","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2024.108076_b1050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.31887\/DCNS.2020.22.1\/macrocq","article-title":"Neurodevelopmental disorders-the history and future of a diagnostic concept","volume":"22","author":"Morris-Rosendahl","year":"2020","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b1055","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/aur.2696","article-title":"Global prevalence of autism: A systematic review update","volume":"15","author":"Zeidan","year":"2022","journal-title":"Autism Res."},{"key":"10.1016\/j.bioorg.2024.108076_b1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108910","article-title":"CNS pharmacology of NKCC1 inhibitors","volume":"205","author":"L\u00f6scher","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2024.108076_b1065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.neuron.2020.08.030","article-title":"LTP Induction Boosts Glutamate Spillover by Driving Withdrawal of Perisynaptic Astroglia","volume":"108","author":"Henneberger","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.bioorg.2024.108076_b1070","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tins.2017.07.001","article-title":"NKCC1 Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders","volume":"40","author":"Ben-Ari","year":"2017","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b1075","doi-asserted-by":"crossref","first-page":"10203","DOI":"10.1021\/acs.jmedchem.1c00603","article-title":"Design, Synthesis,In VitroandIn VivoCharacterization of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in down Syndrome","volume":"64","author":"Borgogno","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1080","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.chempr.2020.06.017","article-title":"Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders","volume":"6","author":"Savardi","year":"2020","journal-title":"Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1085","doi-asserted-by":"crossref","unstructured":"A. Savardi, A. Patricelli Malizia, M. De Vivo, L. Cancedda, M. Borgogno, Preclinical Development of the Na-K-2Cl Co-transporter-1 (NKCC1) Inhibitor ARN23746 for the Treatment of Neurodevelopmental Disorders, ACS Pharmacol Transl Sci 6 (2023) 1\u201311. https:\/\/doi.org\/10.1021\/acsptsci.2c00197.","DOI":"10.1021\/acsptsci.2c00197"},{"key":"10.1016\/j.bioorg.2024.108076_b1090","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021110169","article-title":"Cryo\u2010EM structure of the human NKCC1 transporter reveals mechanisms of ion coupling and specificity","volume":"41","author":"Neumann","year":"2022","journal-title":"EMBO J"},{"key":"10.1016\/j.bioorg.2024.108076_b1095","doi-asserted-by":"crossref","first-page":"17118","DOI":"10.1021\/acs.jmedchem.3c02030","article-title":"Development of Ligands for the Super Conserved Orphan G Protein-Coupled Receptor GPR27 with Improved Efficacy and Potency","volume":"66","author":"Pillaiyar","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1100","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1006\/bbrc.2000.2829","article-title":"An Evolutionarily Conserved G-Protein Coupled Receptor Family, SREB, Expressed in the Central Nervous System","volume":"272","author":"Matsumoto","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bioorg.2024.108076_b1105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002449","article-title":"An siRNA Screen in Pancreatic Beta Cells Reveals a Role for Gpr27 in Insulin Production","volume":"8","author":"Ku","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.bioorg.2024.108076_b1110","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1111\/bph.13452","article-title":"Identifying ligands at orphan GPCRs: current status using structure-based approaches","volume":"173","author":"Ngo","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bioorg.2024.108076_b1115","doi-asserted-by":"crossref","unstructured":"N. Dupuis, C. Laschet, D. Franssen, M. Szpakowska, J. Gilissen, P. Geubelle, A. Soni, A.-S. Parent, B. Pirotte, A. Chevign\u00e9, J.-C. Twizere, J. Hanson, Activation of the Orphan G Protein\u2013Coupled Receptor GPR27 by Surrogate Ligands Promotes <em>\u03b2<\/em>-Arrestin 2 Recruitment, Mol Pharmacol 91 (2017) 595 LP \u2013 608. https:\/\/doi.org\/10.1124\/mol.116.107714.","DOI":"10.1124\/mol.116.107714"},{"key":"10.1016\/j.bioorg.2024.108076_b1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113777","article-title":"Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27","volume":"225","author":"Pillaiyar","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.pbb.2008.05.010","article-title":"Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - A short review","volume":"90","author":"Sv\u00ed\u017eensk\u00e1","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bioorg.2024.108076_b1135","doi-asserted-by":"crossref","unstructured":"R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P.H. Alexander, V. Di Marzo, M.R. Elphick, P.J. Greasley, H.S. Hansen, G. Kunos, K. Mackie, R. Mechoulam, R.A. Ross, International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2, Pharmacol Rev 62 (2010) 588\u2013631. https:\/\/doi.org\/10.1124\/pr.110.003004.","DOI":"10.1124\/pr.110.003004"},{"key":"10.1016\/j.bioorg.2024.108076_b1140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.phrs.2019.02.029","article-title":"Role of endocannabinoid system in dopamine signalling within the reward circuits affected by chronic pain","volume":"143","author":"Mlost","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bioorg.2024.108076_b1145","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1021\/jm031019q","article-title":"Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB1 Cannabinoid Receptor Antagonists","volume":"47","author":"Lange","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1150","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1016\/j.bmcl.2016.08.018","article-title":"Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators","volume":"26","author":"Greig","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b1155","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1124\/pharmrev.120.000131","article-title":"Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels","volume":"73","author":"Hansen","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bioorg.2024.108076_b1160","first-page":"335","article-title":"The activation mechanism of class-C G-protein coupled receptors","volume":"96","author":"Pin","year":"2004","journal-title":"Biol Cell"},{"key":"10.1016\/j.bioorg.2024.108076_b1165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn3504","article-title":"NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease","volume":"14","author":"Paoletti","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b1170","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1124\/jpet.110.172544","article-title":"Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors","volume":"335","author":"Bettini","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2024.108076_b1175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejmech.2017.02.018","article-title":"Systematic variation of the benzenesulfonamide part of the GluN2A selective NMDA receptor antagonist TCN-201","volume":"129","author":"M\u00fcller","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1180","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.neuron.2016.08.014","article-title":"Structural Basis for Negative Allosteric Modulation of GluN2A-Containing NMDA Receptors","volume":"91","author":"Yi","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.bioorg.2024.108076_b1185","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1021\/acsmedchemlett.8b00395","article-title":"Di-aryl Sulfonamide Motif Adds \u03c0-Stacking Bulk in Negative Allosteric Modulators of the NMDA Receptor","volume":"10","author":"Summer","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b1190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148129","article-title":"MPX-004 and MPX-007: New pharmacological tools to study the physiology of nmda receptors containing the GluN2A Subunit","volume":"11","author":"Volkmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2024.108076_b1195","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.bmcl.2011.04.017","article-title":"Quinazolinedione sulfonamides: A novel class of competitive AMPA receptor antagonists with oral activity","volume":"21","author":"Koller","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b1200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/cmdc.201600467","article-title":"Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist","volume":"12","author":"Orain","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2024.108076_b1205","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1517\/13543784.2014.848854","article-title":"BGG492 (selurampanel), an AMPA\/kainate receptor antagonist drug for epilepsy","volume":"23","author":"Faught","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bioorg.2024.108076_b1210","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1471-4159.2004.02526.x","article-title":"AMPA protects cultured neurons against glutamate excitotoxicity through a phosphatidylinositol 3-kinase-dependent activation in extracellular signal-regulated kinase to upregulate BDNF gene expression","volume":"90","author":"Wu","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.bioorg.2024.108076_b1215","doi-asserted-by":"crossref","unstructured":"M. Mackowiak, M.J. O\u2019neill, C.A. Hicks, D. Bleakman, P. Skolnick, An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study, 2002. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/S0028-3908(02)00066-7.","DOI":"10.1016\/S0028-3908(02)00066-7"},{"key":"10.1016\/j.bioorg.2024.108076_b1220","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1021\/acschemneuro.5b00318","article-title":"Synthesis and Pharmacology of Mono-, Di-, and Trialkyl-Substituted 7-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxides Combined with X-ray Structure Analysis to Understand the Unexpected Structure-Activity Relationship at AMPA Receptors","volume":"7","author":"Larsen","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bioorg.2024.108076_b1225","series-title":"Receptor","first-page":"150","article-title":"7-Chloro-5-(furan-3-yl)-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-Dioxide as Positive Allosteric Modulator of \u03b1-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA)","author":"Citti","year":"2016"},{"key":"10.1016\/j.bioorg.2024.108076_b1230","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jmb.2009.07.002","article-title":"Distinct Structural Features of Cyclothiazide Are Responsible for Effects on Peak Current Amplitude and Desensitization Kinetics at iGluR2","volume":"391","author":"Hald","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bioorg.2024.108076_b1235","volume":"250","author":"Eric","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1240","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1021\/jm0002836","article-title":"Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)-propanoic acid (AMPA) receptors [1]","volume":"43","author":"Ornstein","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1245","unstructured":"Macklin Brian Arnold, Thomas John Bleisch, George William Cuff, Paul Leslie Ornstein, Dennis Michael Zimmerman, Sulfonamide derivatives WO2001090057A1, 2001."},{"key":"10.1016\/j.bioorg.2024.108076_b1250","doi-asserted-by":"crossref","unstructured":"M.J. O\u2019neill, T.K. Murray, M.P. Clay, T. Lindstrom, C.R. Yang, E.S. Nisenbaum, LY503430: Pharmacology Pharmacokinetics, and Effects in Rodent Models of Parkinson\u2019s Disease 2005.","DOI":"10.1111\/j.1527-3458.2005.tb00037.x"},{"key":"10.1016\/j.bioorg.2024.108076_b1255","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1124\/jpet.117.245050","article-title":"HBT1, a novel ampa receptor potentiator with lower agonistic effect, avoided bell-shaped response in in vitro BDNF productions","volume":"364","author":"Kunugi","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2024.108076_b1260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116151","article-title":"AMPA receptor neurotransmission and therapeutic applications: A comprehensive review of their multifaceted modulation","volume":"266","author":"Qneibi","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1265","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jmedchem.5b00300","article-title":"The discovery and characterization of the \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3 S,4 S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242)","volume":"58","author":"Shaffer","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.108076_b1270","unstructured":"Masakuni Kori, Toshihiro Imaeda, Shinji Nakamura, Masashi Toyofuku, Eiji Honda, Yasutomi Asano, Osamu Ujikawa, Michiyo Mochizuki, Heterocyclic compound and use thereof US 2012\/0077799 A1, 2012."},{"key":"10.1016\/j.bioorg.2024.108076_b1275","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pbb.2019.06.004","article-title":"TAK-137, an AMPA receptor potentiator with little agonistic effect, produces antidepressant-like effect without causing psychotomimetic effects in rats","volume":"183","author":"Suzuki","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bioorg.2024.108076_b1280","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.479","article-title":"Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia","volume":"7","author":"Tanaka","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.bioorg.2024.108076_b1285","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-022-02148-w","article-title":"Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers","volume":"12","author":"Dijkstra","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.bioorg.2024.108076_b1290","unstructured":"https:\/\/neurocrine.gcs-web.com\/news-releases\/news-release-details\/neurocrine-biosciences-reports-positive-phase-2-data-nbi-1065845."},{"key":"10.1016\/j.bioorg.2024.108076_b1295","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1016\/j.bmcl.2010.07.007","article-title":"Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu 4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS)","volume":"20","author":"Engers","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.108076_b1300","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/co1000508","article-title":"Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlu4","volume":"13","author":"Cheung","year":"2011","journal-title":"ACS Comb Sci"},{"key":"10.1016\/j.bioorg.2024.108076_b1305","unstructured":"NCT01739348, https:\/\/clinicaltrials.gov\/study\/NCT01739348?cond=NCT01739348&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1310","unstructured":"NCT00890890, https:\/\/clinicaltrials.gov\/study\/NCT00890890?cond=NCT00890890&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1315","unstructured":"NCT00479219, https:\/\/clinicaltrials.gov\/study\/NCT00479219?cond=NCT00479219&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1320","unstructured":"NCT01712074, https:\/\/clinicaltrials.gov\/study\/NCT01712074?cond=NCT01712074&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1325","unstructured":"NCT02580305, https:\/\/clinicaltrials.gov\/study\/NCT02580305?cond=NCT02580305&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1330","unstructured":"NCT05397639, https:\/\/clinicaltrials.gov\/study\/NCT05397639?cond=NCT05397639&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1335","unstructured":"NCT04338997, https:\/\/clinicaltrials.gov\/study\/NCT04338997?cond=NCT04338997&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1340","unstructured":"NCT03740178, (https:\/\/clinicaltrials.gov\/study\/NCT03740178?cond=NCT03740178&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1345","unstructured":"NCT05136690, https:\/\/clinicaltrials.gov\/study\/NCT05136690?cond=NCT05136690&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1350","unstructured":"NCT03792490, https:\/\/clinicaltrials.gov\/study\/NCT03792490?cond=NCT03792490&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1355","unstructured":"NCT01935518, https:\/\/clinicaltrials.gov\/study\/NCT01935518?cond=NCT01935518&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1360","unstructured":"NCT05218668, https:\/\/clinicaltrials.gov\/study\/NCT05218668?cond=NCT05218668&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1365","unstructured":"NCT04091438, https:\/\/clinicaltrials.gov\/study\/NCT04091438?cond=NCT04091438&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1370","unstructured":"NCT05180890, https:\/\/clinicaltrials.gov\/study\/NCT05180890?cond=NCT05180890&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1375","unstructured":"NCT03332784, https:\/\/clinicaltrials.gov\/study\/NCT03332784?cond=NCT03332784&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1380","unstructured":"NCT04820842, https:\/\/clinicaltrials.gov\/study\/NCT04820842?cond=NCT04820842&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1385","unstructured":"NCT04096560, https:\/\/clinicaltrials.gov\/study\/NCT04096560?cond=NCT04096560&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1390","unstructured":"NCT05687916, https:\/\/clinicaltrials.gov\/study\/NCT05687916?cond=NCT05687916&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1395","unstructured":"NCT05687903, https:\/\/clinicaltrials.gov\/study\/NCT05687903?cond=NCT05687903&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1400","unstructured":"NCT05816382, https:\/\/clinicaltrials.gov\/study\/NCT05816382?cond=NCT05816382&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1405","unstructured":"NCT00380302, https:\/\/clinicaltrials.gov\/study\/NCT00380302?cond=NCT00380302&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1410","unstructured":"NCT00345410, https:\/\/clinicaltrials.gov\/study\/NCT00345410?cond=NCT00345410&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1415","unstructured":"NCT00439634, https:\/\/clinicaltrials.gov\/study\/NCT00439634?cond=NCT00439634&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1420","unstructured":"NCT00784212,. https:\/\/clinicaltrials.gov\/study\/NCT00784212?cond=NCT00784212&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1425","unstructured":"NCT01338805, https:\/\/clinicaltrials.gov\/study\/NCT01338805?cond=NCT01338805&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1430","unstructured":"NCT00892203,). https:\/\/clinicaltrials.gov\/study\/NCT00892203?cond=NCT00892203&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1435","unstructured":"NCT01649050, https:\/\/clinicaltrials.gov\/study\/NCT01649050?cond=NCT01649050&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1440","unstructured":"NCT00051909, https:\/\/clinicaltrials.gov\/study\/NCT00051909?cond=NCT00051909&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1445","unstructured":"NCT00843518, https:\/\/clinicaltrials.gov\/study\/NCT00843518?cond=NCT00843518&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1450","unstructured":"NCT02855411, https:\/\/clinicaltrials.gov\/study\/NCT02855411?cond=NCT02855411&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1455","unstructured":"NCT02332798, https:\/\/clinicaltrials.gov\/study\/NCT02332798?cond=NCT02332798&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1460","unstructured":"NCT01749098, https:\/\/clinicaltrials.gov\/study\/NCT01749098?cond=NCT01749098&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1465","unstructured":"NCT02163915, https:\/\/clinicaltrials.gov\/study\/NCT02163915?cond=NCT02163915&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1470","unstructured":"NCT03312894, https:\/\/clinicaltrials.gov\/search?cond=NCT03312894."},{"key":"10.1016\/j.bioorg.2024.108076_b1475","unstructured":"NCT05203341, https:\/\/clinicaltrials.gov\/study\/NCT05203341?cond=NCT05203341&rank=1."},{"key":"10.1016\/j.bioorg.2024.108076_b1480","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/co400012m","article-title":"Building a sulfonamide library by eco-friendly flow synthesis","volume":"15","author":"Gioiello","year":"2013","journal-title":"ACS Comb Sci"},{"key":"10.1016\/j.bioorg.2024.108076_b1485","doi-asserted-by":"crossref","first-page":"10958","DOI":"10.1021\/acs.joc.0c01044","article-title":"Sustainable Synthesis of a Potent and Selective 5-HT7Receptor Antagonist Using a Mechanochemical Approach","volume":"85","author":"Canale","year":"2020","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bioorg.2024.108076_b1490","doi-asserted-by":"crossref","first-page":"16156","DOI":"10.1021\/acssuschemeng.3c04023","article-title":"Multistep Mechanochemical Synthesis of PZ-1190, a Multitarget Antipsychotic Agent","volume":"11","author":"Canale","year":"2023","journal-title":"ACS Sustain Chem Eng"},{"key":"10.1016\/j.bioorg.2024.108076_b1495","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1002\/anie.202016164","article-title":"Metal-Free Electrochemical Synthesis of Sulfonamides Directly from (Hetero)arenes, SO2, and Amines","volume":"60","author":"Blum","year":"2021","journal-title":"Angewandte Chemie - International Edition"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824009817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824009817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T02:01:14Z","timestamp":1758852074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824009817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":295,"alternative-id":["S0045206824009817"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108076","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current development in sulfonamide derivatives to enable CNS-drug discovery","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108076"}}